Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: In vitro, in vivo, and outcomes investigation

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 2, 2014, Pages 381-388

  Teo, Yi Ling ^a,b   Chong, Xue Jing ^a   Chue, Xiu Ping ^a   Chau, Noan Minh ^b   Tan, Min Han ^b   Kanesvaran, Ravindran ^b   Wee, Hwee Lin ^a   Ho, Han Kiat ^a   Chan, Alexandre ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Dermatological toxicity; HRQoL; Metastatic renal cell carcinoma; SU12662; Sunitinib

Indexed keywords

DRUG METABOLITE; N DEETHYLSUNITINIB; SUNITINIB;

ADULT; ADVERSE OUTCOME; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT HISTORY OF NEPHRECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RASH; SKIN TOXICITY; TREATMENT OUTCOME; XEROSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; HAND-FOOT SYNDROME; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; QUALITY OF LIFE; SKIN;

EID: 84896032959     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2360-1     Document Type: Article

References (29)

1. Clinical practice guidelines in oncology, kidney cancer (2013) National Comprehensive Cancer Network (NCCN) www.NCCN.org
2. Pfizer. Sutent (sunitinib) capsules prescribing information. http:// www.accessdata.fda.gov/drugsatfda-docs/label/2012/021938s021s022s023lbl.pdf
3. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491-500 (Pubitemid 40903630)
4. Chu D, Lacouture ME, Weiner E, Wu S (2009) Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 7:11-19
5. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35 (Pubitemid 46630490)
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
7. Rosenbaum S, Wu S, Newman M, West D, Kuzel T, Lacouture M (2008) Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 16:557-566
8. Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, Na S, Kim CS, Hong JH, Hong B, Song C, Ahn H (2010) The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 40:980-985
9. Lacouture ME, Reilly LM, Gerami P, Guitart J (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19:1955-1961
10. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66:357-371
11. Ooi WS, Lin KK, Khoo V, Kanesvaran R, Chan A (2009) Efficacy and toxicities of a reduced dose sunitinib regimen in metastatic renal cell carcinoma. Paper presented at the National Cancer Research Institute, London
12. Thomas F, Rochaix P, White-Koning M, Hennebelle I, Sarini J, Benlyazid A, Malard L, Lefebvre JL, Chatelut E, Delord JP (2009) Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 45:2316-2323
13. Sibaud V, Dalenc F, Chevreau C, Roché H, Delord J-P, Mourey L, Lacaze J-L, Rahhali N, Taïeb C (2011) HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 16:1469-1478
14. Etienne-Grimaldi MC, Renee N, Izzedine H, Milano G (2009) A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 877:3757-3761
15. Blanchet B, Saboureau C, Benichou AS, Billemont B, Taieb F, Ropert S, Dauphin A, Goldwasser F, Tod M (2009) Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta 404:134-139
16. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
17. Sylvester PW (2011) Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol 716:157-168
18. Hong M, Jeung H, Chung H, Ahn J, Roh J, Noh S, Rha S (2009) Predictive factors associated with clinical outcome and safety in Korean patients with metastatic renal cell carcinoma treated with sunitinib. J Clin Oncol 27:suppl; abstr e16111
19. Yang CH, Chuang CK, Hsieh JJ, Chang JW (2010) Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma. Expert Opin Drug Saf 9:459-470
20. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761-771 (Pubitemid 18089976)
21. Vazquez R, Nelson MR, Guzman JJ, Corun CM, Steinberg M (2004) Immortalized human keratinocytes: a model system to study the efficacy of therapeutic drugs in response to the chemical warfare agent sulfur mustard (HD). Electron J Biotechnol 7:124-129
22. Aparicio-Gallego G, Blanco M, Figueroa A, García-Campelo R, Valladares-Ayerbes M, Grande-Pulido E, Antón-Aparicio L (2011) New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther 10:2215-2223
23. Porta C, Paglino C, Imarisio I, Bonomi L (2007) Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 7:127-134
24. Detmar M, Yeo K-T, Nagy JA, van de Water L, Brown LF, Berse B, Elicker BM, Ledbetter S, Dvorak HF (1995) Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 105:44-50
25. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001-1011
26. Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW (2006) Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 24:5786-5788 (Pubitemid 46631323)
27. Man XY, Yang XH, Cai SQ, Yao YG, Zheng M (2006) Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Mol Med 12:127-136
28. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391 (Pubitemid 32268418)
29. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296 (Pubitemid 34032623)